ATE345795T1 - 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen - Google Patents
1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungenInfo
- Publication number
- ATE345795T1 ATE345795T1 AT04736979T AT04736979T ATE345795T1 AT E345795 T1 ATE345795 T1 AT E345795T1 AT 04736979 T AT04736979 T AT 04736979T AT 04736979 T AT04736979 T AT 04736979T AT E345795 T1 ATE345795 T1 AT E345795T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonylamino
- oxo
- inhibitors
- phenyl
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0314299.9A GB0314299D0 (en) | 2003-06-19 | 2003-06-19 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE345795T1 true ATE345795T1 (de) | 2006-12-15 |
Family
ID=27636926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04736979T ATE345795T1 (de) | 2003-06-19 | 2004-06-17 | 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US7329685B2 (de) |
EP (1) | EP1635817B1 (de) |
JP (1) | JP2006527729A (de) |
AT (1) | ATE345795T1 (de) |
DE (1) | DE602004003380T2 (de) |
ES (1) | ES2276307T3 (de) |
GB (1) | GB0314299D0 (de) |
WO (1) | WO2004110435A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
WO2007059952A2 (en) * | 2005-11-24 | 2007-05-31 | Glaxo Group Limited | 1-benzazepine-3-sulfonylamino-2-pyrrloridones as factor xa inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202344A (en) | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
US6034093A (en) | 1995-06-07 | 2000-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO2002002519A2 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
US6348600B1 (en) | 2001-02-20 | 2002-02-19 | Toray Industries, Inc. | Methods for making optically active 3-aminopyrrolidine-2,5-dione derivative and optically active 3-aminopyrrolidine derivative |
US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
GB0127568D0 (en) * | 2001-11-16 | 2002-01-09 | Glaxo Group Ltd | Chemical compounds |
GB0130705D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Chemical compounds |
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
-
2003
- 2003-06-19 GB GBGB0314299.9A patent/GB0314299D0/en not_active Ceased
-
2004
- 2004-06-17 WO PCT/EP2004/006592 patent/WO2004110435A1/en active IP Right Grant
- 2004-06-17 DE DE602004003380T patent/DE602004003380T2/de not_active Expired - Fee Related
- 2004-06-17 ES ES04736979T patent/ES2276307T3/es not_active Expired - Lifetime
- 2004-06-17 EP EP04736979A patent/EP1635817B1/de not_active Expired - Lifetime
- 2004-06-17 AT AT04736979T patent/ATE345795T1/de not_active IP Right Cessation
- 2004-06-17 JP JP2006515988A patent/JP2006527729A/ja not_active Withdrawn
- 2004-06-17 US US10/561,545 patent/US7329685B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1635817A1 (de) | 2006-03-22 |
JP2006527729A (ja) | 2006-12-07 |
US7329685B2 (en) | 2008-02-12 |
DE602004003380D1 (de) | 2007-01-04 |
DE602004003380T2 (de) | 2007-10-04 |
WO2004110435A1 (en) | 2004-12-23 |
EP1635817B1 (de) | 2006-11-22 |
US20060148879A1 (en) | 2006-07-06 |
GB0314299D0 (en) | 2003-07-23 |
ES2276307T3 (es) | 2007-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE430139T1 (de) | Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-( - (3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen | |
DK1853602T3 (da) | Kemiske forbindelser | |
DK1853588T3 (da) | Kemiske forbindelser | |
ATE497496T1 (de) | 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
ATE402180T1 (de) | Verbindungen zur behandlung von dyslipidemie | |
TW200510317A (en) | Caspase inhibitors and uses thereof | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE542531T1 (de) | Nitrofuran-verbindungen zur behandlung von krebs und angiogenese | |
DK1483251T3 (da) | C3-cyano-epothilon-derivater | |
EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
ATE482933T1 (de) | Sulfopyrrolderivate | |
ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
DE602005022284D1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
ATE345795T1 (de) | 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen | |
EA200600549A1 (ru) | Ингибиторы каспаз в качестве материала для покрытия медицинских продуктов для ингибирования рестеноза | |
DE602004003829D1 (de) | 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |